Janux Therapeutics (JANX) Receivables - Other (2023 - 2026)
Janux Therapeutics (JANX) posted quarterly Receivables - Other of $7.5 million for Q1 2026, up 33.63% year-over-year from $5.6 million in Q1 2025, and up 16.1% quarter-over-quarter from $6.4 million in Q4 2025.
Janux Therapeutics (JANX) Receivables - Other (2023 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Receivables - Other for 4 consecutive years, with $7.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Other rose 33.63% year-over-year to $7.5 million; the TTM figure through Mar 2026 stood at $7.5 million (up 33.63% YoY), while the FY2025 annual figure was $6.4 million, up 19.46% from the prior year.
- Receivables - Other climbed to $7.5 million in Q1 2026 per JANX's latest filing, from $6.4 million in the prior quarter.
- Across five years, Receivables - Other topped out at $7.5 million in Q1 2026 and bottomed at $2.2 million in Q4 2023.
- Historically, Receivables - Other has averaged $5.2 million across 4 years, with a median of $5.5 million in 2024.
- Annual changes were most pronounced in 2024 — Receivables - Other surged 149.01% — and 2025, when it gained 19.46%.
- Janux Therapeutics' Receivables - Other stood at $2.2 million in 2023, then soared by 149.01% to $5.4 million in 2024, then climbed by 19.46% to $6.4 million in 2025, then grew by 16.1% to $7.5 million in 2026.
- Business Quant data shows JANX's Receivables - Other at $7.5 million in Q1 2026, $6.4 million in Q4 2025, and $6.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.18 Mn |
| Jun 30, 2026 | 6.18 Mn |
| Mar 31, 2026 | 7.46 Mn |
| Mar 31, 2026 | 7.46 Mn |
| Dec 31, 2025 | 6.43 Mn |
| Dec 31, 2025 | 6.43 Mn |
| Sep 30, 2025 | 6.32 Mn |
| Sep 30, 2025 | 6.32 Mn |
| Jun 30, 2025 | 5.69 Mn |
| Jun 30, 2025 | 5.69 Mn |
| Mar 31, 2025 | 5.59 Mn |
| Mar 31, 2025 | 5.59 Mn |
| Dec 31, 2024 | 5.38 Mn |
| Dec 31, 2024 | 5.38 Mn |
| Sep 30, 2024 | 4.45 Mn |
| Sep 30, 2024 | 4.45 Mn |
| Jun 30, 2024 | 4.56 Mn |
| Jun 30, 2024 | 4.56 Mn |
| Mar 31, 2024 | 3.89 Mn |
| Mar 31, 2024 | 3.89 Mn |